Most gastrointestinal stromal tumors (GISTs) contain KIT or PDGFRA kinase gain-of-function mutations, and therefore respond clinically to imatinib and other tyrosine kinase inhibitor (TKI) therapies. However, clinical progression subsequently results from selection of TKI-resistant clones, typically containing secondary mutations in the KIT kinase domain, which can be heterogeneous between and within GIST metastases in a given patient. TKI-resistant KIT oncoproteins require HSP90 chaperoning and are potently inactivated by HSP90 inhibitors, but clinical applications in GIST patients are constrained by the toxicity resulting from concomitant inactivation of various other HSP90 client proteins, beyond KIT and PDGFRA. To identify novel targets responsible for KIT oncoprotein function, we performed parallel genome-scale short hairpin RNA (shRNA)-mediated gene knockdowns in KIT-mutant GIST-T1 and GIST882. GIST cells were infected with a lentiviral shRNA pooled library targeting 11 194 human genes, and allowed to proliferate for 5-7 weeks, at which point assessment of relative hairpin abundance identified the HSP90 cofactor, CDC37, as one of the top six GIST-specific essential genes. Validations in treatment-naive (GIST-T1, GIST882) vs imatinib-resistant GISTs (GIST48, GIST430) demonstrated that: (1) CDC37 interacts with oncogenic KIT; (2) CDC37 regulates expression and activation of KIT and downstream signaling intermediates in GIST; and (3) unlike direct HSP90 inhibition, CDC37 knockdown accomplishes prolonged KIT inhibition (420 days) in GIST. These studies highlight CDC37 as a key biologic vulnerability in both imatinib-sensitive and imatinibresistant GIST. CDC37 targeting is expected to be selective for KIT/PDGFRA and a subset of other HSP90 clients, and thereby represents a promising strategy for inactivating the myriad KIT/PDGFRA oncoproteins in TKI-resistant GIST patients.
INTRODUCTION
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Gain-of-function mutation of the receptor tyrosine kinases KIT or PDGFRA is a crucial oncogenic event in most GISTs, detectable in 85-90% of cases. 1, 2 Therapeutic targeting of the KIT/PDGFRA oncoproteins with imatinib enables clinical responses in 80% of inoperable GIST patients 3 and has also improved progression-free survival as an adjuvant treatment postoperatively in patients with high-risk localized GIST. 4 Although dramatic therapeutic responses to imatinib are the norm in patients with inoperable GIST, clinical complete responses are rare (p5%) and up to 90% of responding patients eventually develop secondary resistance, with median time to progression of 2 years with first-line tyrosine kinase inhibitor (TKI) therapy. 5, 6 Clinical progression during imatinib therapy occurs typically at multiple metastatic sites because of a variety of molecular imatinib resistance mechanisms of which KIT/PDGFRA kinase domain secondary mutations in the ATP-binding pocket or activation loop regions are the most frequent. 7 Less common imatinib resistance mechanisms include KIT gene amplification, and activation of kinases downstream of KIT/PDGFRA. 8, 9 Notably, at time of progression on imatinib there can be substantial heterogeneity in these molecular resistance mechanisms within and between metastases in an individual patient. The multikinase inhibitor sunitinib is the only currently approved therapy for advanced GIST following resistance to imatinib; although sunitinib is a potent inhibitor of imatinib resistance caused by mutations in the KIT ATP-binding pocket, this therapy is less effective against imatinib resistance mutations affecting the KIT kinase activation loop. 10 Therefore, treatment of the entire spectrum of imatinib resistance mutations, particularly those encoded by KIT exons 17 and 18, as well as PDGFRA exon 18 remains an urgent unmet medical need in GIST.
The extreme dependence of GIST cells on KIT/PDGFRA activation is a striking example of oncogene addiction, 11 in which adaptations are required to optimize and stabilize the essential KIT/PDGFRA oncoproteins, creating secondary dependencies on proteins that are requisite for KIT/PDGFRA transforming activity. One such biologic dependency is HSP90 chaperoning, required for folding, localization and stabilization of the mutant KIT/PDGFRA oncoproteins in GIST. 12 Preclinical validations have shown compelling responses to HSP90 inhibition in GIST, in vitro and in vivo: after HSP90 inhibition by a variety of compounds, KIT oncoproteins are rapidly degraded, with antiproliferative and pro-apopotic consequences. 12, 13 However, clinical translation of HSP90 targeting has been challenging, presumably because inhibition of HSP90 also targets HSP90-dependent, non-oncogenic, client proteins limiting the tolerance to chronic and potent HSP90 inhibition. These considerations, together with issues relating to trial design and patient selection criteria, might explain why initial clinical trials of ansamycin-analog HSP90 inhibition in GIST-although showing evidence of biological activity-have had low response rates accompanied by toxicity.
14 To identify candidate targets that might have greater specificity for KIT-mutant GIST, we undertook a genome-scale functional screen in which stable gene knockdowns were achieved by RNA interference.
RESULTS AND DISCUSSION
shRNA pooled library screen performance in GIST-T1 and GIST882 cells Reproducibility of short hairpin RNA (shRNA) enrichment and depletion profiles was evaluated across the experimental replicates, as a quality control. The GIST882 and GIST-T1 screen replicates clustered closely within each cell line by both unsupervised and consensus clustering of shRNA depletion and enrichment profiles, attesting to the robustness of the screens. In addition, the GIST882 and GIST-T1 replicates clustered next to each other when compared with a reference data set of 12 publicly available cancer cell line data sets, 15 as well as after linkage analysis in the context of additional unpublished sarcoma cell lines (Supplementary Figure 1) . A comprehensive list of the 11 194 ranked genes, along with annotation for the shRNA clones, is provided in Supplementary Table 1. CDC37 is essential for GIST cell survival In the pooled proliferation screens, cells carrying shRNAs that targeted proliferation-essential genes were depleted from the cell population over time. Scored according to the second bestscoring shRNA within each hairpin set, 25 out of 56 genes ranked in the top 0.5% of the distribution for both GIST882 and GIST-T1 ( Table 1 , left column). Of these 25 genes, 19 were also within the top 0.5% in at least 8 of 12 comparison non-GIST cancer lines, 15 and were thus identified as 'commonly essential' genes not specific to GIST (Figure 1a ). These genes belonged to functional categories known to be essential in cancer cell lines: regulation of mRNA splicing and processing, protein translation, and ribosome and proteasome structure and function. The other six genes were selectively essential for the two GIST cell lines vs the other lines (bold italic font, Table 1 left column): five of these encode mRNA processing proteins, whereas the remaining gene, CDC37, encodes an HSP90 cofactor. CDC37 is known to coordinate HSP90 chaperoning activity for a subset of HSP90 client proteins, including several kinases, 17, 18 by mechanisms involving Table 1 . Top 0.5% essential genes according to the second bestscoring hairpin in GIST882 and GIST-T1 (n ¼ 56 for each)
GIST882 and GIST-T1 GIST882 only GIST-T1 only HNRPU  RAN  U2AF2  RPS6  RPS3A  CHD4  RPS3  RPS4X  AQR  ASCC3L1  RPS11  NHP2L1  RPL34  RPL7  NDUFA4L2  RPL6  RPSA  EIF5B  USP39  EIF2S2  PHB  SNRPE  EIF1AX  HSPE1  TPR  U2AF1 Abbreviation: GIST, gastrointestinal stromal tumor. Genes in bold font (upper fields) scored top 0.5% in the gene distribution in GIST lines but not in 12 non-GIST reference cancer cell lines of various lineages (described by Luo et al.
15
). Genes in regular font (lower fields) scored top 0.5% in both GIST and the 12 non-GIST reference set. Figure 1 . Primary shRNA pooled screen. Development and applications of the 54K lentiviral shRNA pooled library from the RNAi Consortium (TRC) have been described previously. 16 In brief, GIST cells were infected with a pool of 54 020 viruses targeting 11 194 genes and subjected to puromycin selection. Replicates of 20 million infected GIST-T1 and GIST882 cells were established after the infections and allowed to proliferate independently for 6-7 weeks. Genomic DNA was isolated from final harvests of cultured cells for shRNA amplification and massively parallel sequencing as described previously. 16 The 54 020 shRNAs were ranked by their relative depletion from the cell pool, and the corresponding 11 194 genes were then scored according to the rank of the second-most depleted shRNA (out of B5 shRNAs targeting each gene), using the GENE-E program (http://www.broadinstitute.org/cancer/software/GENE-E/ download.html). (a) Most of the top 0.5% essential genes for GIST882 and GIST-T1 were commonly essential genes, based on their ranks in at least 8 of 12 non-GIST cancer cell lines of various lineages. However, six genes, including CDC37, were selectively essential in GIST882 and GIST-T1 compared with the non-GIST lines. (b) Gene ranks (red) and shRNA ranks (black) corresponding to CDC37, KIT and ETV1 in GIST882 cells. Essential genes (oncogenes) rank on the top of the distribution.
formation of CDC37-kinase-HSP90 complexes. 19 These observations suggest that CDC37 targeting might be a selective approach to derailing HSP90-mediated KIT oncoprotein chaperoning in GIST. The KIT oncogenic driver and the GISTlineage-related transcription factor ETV1 also scored as essential genes in these primary screens and serve as positive controls (Figure 1b) . In GIST-T1 cells, only one out of the five shRNAs targeting KIT was highly depleted, so KIT did not rank highly in the essential genes list; however, subsequent experiments showed that only the strongly depleted shRNA was highly effective at suppressing KIT in these cells (B70% knockdown) whereas the other four shRNAs produced o30% knockdown of KIT (Supplementary Figure 2) . CDC37 interacts with KIT in GIST, maintaining KIT expression and cell survival CDC37 expression was demonstrated by immunoblotting in the GIST cell lines (Figure 2) . Interaction between CDC37 and KIT in these GISTs was demonstrated by co-immunoprecipitations using KIT and CDC37 antibodies in KIT-positive GIST882 and GIST-T1 cells, with KIT-negative GIST48B cells serving as a negative control Figure 2 . CDC37 expression and CDC37-KIT co-immunoprecipitations in GIST cell lines, demonstrating CDC37:KIT interaction. Wholecell lysates, electrophoresis and immunoblotting were carried out as described previously. 20 Figure 3. Persistent inhibition of KIT oncoprotein expression and phosphorylation, and decreased downstream signaling pathway activation in KITdependent GIST cells on shRNA-mediated CDC37 knockdown. (a) Lentiviral constructs encoding shRNA-specific sequences targeting CDC37 transcripts on the pLKO.1puro backbone were selected from the RNAi Consortium (TRC) library (TRCN0000116632: clone 1; and TRCN0000116633: clone 2; the TRC website is http://www.broadinstitute.org/rnai/trc/lib). Lentivirus preparations and lentiviral infections were performed as described previously. 23 Cells were lysed for immunoblot analysis at 4, 10 and 20 days post-infection; day 10 is shown here. Whole-cell lysates, electrophoresis and immunoblotting were carried out as described previously. 20 (b) shRNA-mediated CDC37 knockdown inhibits viability of GISTs, including those resistant to imatinib (GIST430) and to the ansamycin-type HSP90-inhibitor 17-AAG (GIST882/AAG and GIST-T1/AAG). For cell viability evaluations by bright field microscopy, cell images were obtained using SPOT software (SPOT Imaging Solutions, Sterling Heights, MI, USA) and an Eclipse TE2000-5 inverted microscope (Nikon, Japan). For viability evaluations by ATP-based CellTiter-Glo luminescent assay (Promega, Madison, WI, USA) (c), luciferase-catalyzed luciferin/ATP reactions were measured with a Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale, CA, USA) and normalized to the day 0 and pLKO control reads. (d) Increase in the number of cells in sub-G0 phase of the cell cycle (flow cytometry analysis of propidium iodide-stained DNA content as previously described), 12 10 days after lentiviral infection and puromycin selection.
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( Figure 2 ). CDC37 shRNA-mediated knockdowns resulted in 490% reduction of KIT expression and activation in the KIT-dependent GIST882, GIST430 and GIST-T1 lines (Figure 3a) . KIT inhibition was associated with inactivation of downstream growth and survival signaling intermediates, including AKT. By contrast, AKT was not inhibited by CDC37 knockdown in the KIT-negative cell line GIST48B, suggesting that the observed inhibition of downstream signaling pathways in GIST882, GIST430 and GIST-T1 was KIT dependent (Figure 3a ). CDC37 knockdown, unlike direct HSP90 inhibition, 21 resulted in persistent inhibition of KIT expression for 420 days, indicating that GIST cells have few compensatory pathways for CDC37 function. The above-mentioned biochemical responses to CDC37 knockdown were accompanied by decreased GIST proliferation and survival as assessed by bright field microscopy and CellTiter-Glo assays (Figures 3b and c) . Notably, these responses were also seen in GIST lines resistant to imatinib (GIST430) or to the ansamycin HSP90 inhibitor 17-AAG (GIST-T1/ AAG and GIST882/AAG). CDC37 knockdown induced an increased sub-G0 cell cycle peak, consistent with a pro-apoptotic effect (Figure 3d) .
shRNA-mediated CDC37 knockdown in GIST-T1 cells resulted in decreased tumor growth in vivo, with decreased tumor volume, overall decreased cellularity and decreased mitotic activity in mouse xenografts (Figure 4 ).
Celastrol does not enable selective CDC37:HSP90 pharmacologic inhibition Preclinical pharmacologic validations were attempted using the HSP90:CDC37 interface inhibitor celastrol. 22 However, celastrol Figure 3a) , and celastrol did not result in dramatic dose-dependent inhibition of KIT expression or KIT activation, despite reduced AKT and mitogen-activated protein kinase phosphorylation (Supplementary Figure 3b) . These findings underscore the protean effects of celastrol, which are reported to include proteasome inhibition, 22 and which will likely preclude achieving CDC37:HSP90-inhibitory drug concentrations in the clinical setting. We therefore expect that effective clinical translation of the concepts in this report will require development of more selective CDC37 inhibitors. Opportunities for more selective CDC37 targeting might result from pharmacologic dysregulation of phosphorylation at CDC37 Ser13. This phosphorylation eventmediated by casein kinase 2-is requisite for CDC37 recruitment of kinase clients to the HSP90 complex, whereas CDC37 Ser13 dephosphorylation-mediated by protein phosphatase 5-is then necessary for priming CDC37 for tyrosine phosphorylation by YES1, ultimately enabling CDC37 and client release from the complex. 19 Therefore, strategies targeting casein kinase 2, protein phosphatase 5 or YES1 might inhibit KIT-directed HSP90 functions in GIST.
In summary, we have performed unbiased genome-wide functional screens, which identify CDC37 as a compelling therapeutic target in GIST. CDC37 interacts with KIT oncoproteins in GIST and is an essential enabler of KIT oncogenic function. Preclinical validations highlight the selectivity and efficacy of targeting KIT through CDC37 in GIST, with advantages compared with direct HSP90 targeting including persistent downregulation of KIT expression and selectivity for only a subset of HSP90 client proteins. These observations suggest that selective targeting of CDC37 might be effective and less toxic than chronic HSP90 inhibition in GIST patients. 
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